{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T19:20:13Z","timestamp":1783970413042,"version":"3.55.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100019111","name":"Perron Institute for Neurological and Translational Science","doi-asserted-by":"crossref","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100019111","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Sir Charles Gairdner Hospital","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurochem Res"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s11064-021-03251-y","type":"journal-article","created":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T09:04:22Z","timestamp":1612170262000},"page":"1166-1176","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Comparative Assessment of the Proteolytic Stability and Impact of Poly-Arginine Peptides R18 and R18D on Infarct Growth and Penumbral Tissue Preservation Following Middle Cerebral Artery Occlusion in the Sprague Dawley Rat"],"prefix":"10.1007","volume":"46","author":[{"given":"Diego","family":"Milani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vince W.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirk W.","family":"Feindel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Blacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Bynevelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam B.","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan S.","family":"Anderton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neville W.","family":"Knuckey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno P.","family":"Meloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,1]]},"reference":[{"issue":"1","key":"3251_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1706442","volume":"378","author":"RG Nogueira","year":"2018","unstructured":"Nogueira RG, Jadhav AP, Haussen DC, Bonafe A, Budzik RF, Bhuva P et al (2018) DAWN trial investigators. Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct. N Engl J Med 378(1):11\u201321","journal-title":"N Engl J Med"},{"issue":"8","key":"3251_CR2","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1161\/STROKEAHA.115.009688","volume":"46","author":"MD Hill","year":"2015","unstructured":"Hill MD, Goyal M, Demchuk AM, Fisher M (2015) Ischemic stroke tissue-window in the new era of endovascular treatment. Stroke 46(8):2332\u20132334","journal-title":"Stroke"},{"issue":"1","key":"3251_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/svn-2018-000211","volume":"4","author":"D Wang","year":"2019","unstructured":"Wang D, Wang Y (2019) Tissue window, not the time window, will guide acute stroke treatment. Stroke Vasc Neurol 4(1):1\u20132","journal-title":"Stroke Vasc Neurol"},{"issue":"Suppl E","key":"3251_CR4","doi-asserted-by":"publisher","first-page":"E157","DOI":"10.1093\/eurheartj\/suaa083","volume":"22","author":"D Toni","year":"2020","unstructured":"Toni D, Risitano A, Gentile L (2020) A revolution in stroke therapy: reperfusion therapy effective even if late. Eur Heart J 22(Suppl E):E157\u2013E161","journal-title":"Eur Heart J"},{"issue":"6","key":"3251_CR5","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1038\/jcbfm.2015.11","volume":"35","author":"BP Meloni","year":"2015","unstructured":"Meloni BP, Brookes LM, Clark VW, Cross JL, Edwards AB, Anderton RS et al (2015) Poly-arginine and arginine-rich peptides are neuroprotective in stroke models. J Cereb Blood Flow Metab 35(6):993\u20131004","journal-title":"J Cereb Blood Flow Metab"},{"key":"3251_CR6","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.pharmthera.2015.06.002","volume":"153","author":"BP Meloni","year":"2015","unstructured":"Meloni BP, Milani D, Edwards AB, Anderton RS, O\u2019Hare Doig RL et al (2015) Neuroprotective peptides fused to arginine-rich cell penetrating peptides: neuroprotective mechanism likely mediated by peptide endocytic properties. Pharmacol Ther 153:36\u201354","journal-title":"Pharmacol Ther"},{"key":"3251_CR7","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3389\/fneur.2020.00108","volume":"11","author":"BP Meloni","year":"2020","unstructured":"Meloni BP, Mastaglia FL, Knuckey NW (2020) Cationic arginine-rich peptides (CARPs): a novel class of neuroprotective agents with a multimodal mechanism of action. Front Neurol 11:108","journal-title":"Front Neurol"},{"issue":"1\u20132","key":"3251_CR8","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s11010-019-03646-0","volume":"464","author":"G MacDougall","year":"2020","unstructured":"MacDougall G, Anderton RS, Ouliel E, Junjie Gao J, Redmond SL, Knuckey NW et al (2020) In vitro cellular uptake and neuroprotective efficacy of poly-arginine-18 (R18) and poly-ornithine-18 (O18) peptides: critical role of arginine guanidinium head groups for neuroprotection. Mol Cell Biochem 464(1\u20132):27\u201338","journal-title":"Mol Cell Biochem"},{"key":"3251_CR9","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.nbd.2018.09.010","volume":"121","author":"G MacDougall","year":"2019","unstructured":"MacDougall G, Anderton RS, Mastaglia FL, Knuckey NW, Meloni BP (2019) Mitochondria and neuroprotection in stroke: cationic arginine-rich peptides (CARPS) as a novel class of mitochondria-targeted neuroprotective therapeutics. Neurobiol Dis 121:17\u201333","journal-title":"Neurobiol Dis"},{"issue":"10227","key":"3251_CR10","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/S0140-6736(20)30258-0","volume":"395","author":"MD Hill","year":"2020","unstructured":"Hill MD, Goyal M, Menon BK, Nogueira RG, McTaggart RA, Demchuk AM et al (2020) Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial. Lancet 395(10227):878\u2013887","journal-title":"Lancet"},{"issue":"5","key":"3251_CR11","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1093\/jnen\/nlz014","volume":"78","author":"BP Meloni","year":"2019","unstructured":"Meloni BP, South SM, Gill DA, Marriott AL, D\u00e9ziel RA, Jacques A et al (2019) Poly-arginine peptides R18 and R18D improve functional outcomes after endothelin-1-induced stroke in the Sprague Dawley rat. J Neuropathol Exp Neurol 78(5):426\u2013435","journal-title":"J Neuropathol Exp Neurol"},{"issue":"2","key":"3251_CR12","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s13311-019-00809-1","volume":"17","author":"BP Meloni","year":"2020","unstructured":"Meloni BP, Chen Y, Harrison KA, Nashed JY, Blacker DJ, South SM et al (2020) Poly-arginine peptide-18 (R18) reduces brain injury and improves functional outcomes in a non-human primate stroke model. Neurotherapeutics 17(2):627\u2013634","journal-title":"Neurotherapeutics"},{"issue":"1","key":"3251_CR13","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12868-016-0253-z","volume":"17","author":"D Milani","year":"2016","unstructured":"Milani D, Clark VW, Cross JL, Anderton RS, Knuckey NW, Meloni BP (2016) Poly-arginine peptides reduce infarct volume in a permanent middle cerebral artery rat stroke model. BMC Neurosci 17(1):19","journal-title":"BMC Neurosci"},{"key":"3251_CR14","first-page":"2372710","volume":"2016","author":"D Milani","year":"2016","unstructured":"Milani D, Knuckey NW, Anderton RS, Cross JL, Meloni BP (2016) The R18 poly-arginine peptide is more effective than the TAT\u2013NR2B9c (NA-1) peptide when administered 60 minutes after permanent middle cerebral artery occlusion in the rat. Stroke Res Treat 2016:2372710","journal-title":"Stroke Res Treat"},{"key":"3251_CR15","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.neures.2016.09.002","volume":"114","author":"D Milani","year":"2017","unstructured":"Milani D, Cross JL, Knuckey NW, Blacker DJ, Anderton RS, Meloni BP (2017) Neuroprotective efficacy of R18 poly-arginine and NA-1 (TAT-NR2B9c) peptides following transient middle cerebral artery occlusion in the rat. Neurosci Res 114:9\u201315","journal-title":"Neurosci Res"},{"key":"3251_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0193884","volume":"13","author":"D Milani","year":"2018","unstructured":"Milani D, Bakeberg MC, Cross JL, Clark VW, Anderton RS, Blacker DJ et al (2018) Comparison of neuroprotective efficacy of poly-arginine R18 and R18D (D-enantiomer) peptides following permanent middle cerebral artery occlusion in the Wistar rat and in vitro toxicity studies. PLoS One 13:e0193884","journal-title":"PLoS One"},{"issue":"1","key":"3251_CR17","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13041-018-0352-0","volume":"11","author":"AB Edwards","year":"2018","unstructured":"Edwards AB, Cross JL, Anderton RS, Knuckey NW, Meloni BP (2018) Poly-arginine R18 and R18D (D-enantiomer) peptides reduce infarct volume and improve behavioural outcomes following perinatal hypoxic-ischaemic encephalopathy in the P7 rat. Mol Brain 11(1):8","journal-title":"Mol Brain"},{"issue":"11","key":"3251_CR18","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1002\/jnr.24315","volume":"96","author":"AB Edwards","year":"2018","unstructured":"Edwards AB, Anderton RS, Knuckey NW, Meloni BP (2018) Assessment of therapeutic window for poly-arginine-18D (R18D) in a P7 rat model of perinatal hypoxic-ischaemic encephalopathy. J Neurosci Res 96(11):1816\u20131826","journal-title":"J Neurosci Res"},{"issue":"3","key":"3251_CR19","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1111\/j.1365-2141.2005.05444.x","volume":"129","author":"G Cesarman-Maus","year":"2005","unstructured":"Cesarman-Maus G, Hajjar KA (2005) Molecular mechanisms of fibrinolysis. Br J Haematol 129(3):307\u2013321","journal-title":"Br J Haematol"},{"issue":"5","key":"3251_CR20","first-page":"990","volume":"18","author":"HJ Jung","year":"2008","unstructured":"Jung HJ, Jeong KS, Lee DG (2008) Effective antibacterial action of tat (47-58) by increased uptake into bacterial cells in the presence of trypsin. J Microbiol Biotechnol 18(5):990\u2013996","journal-title":"J Microbiol Biotechnol"},{"issue":"4","key":"3251_CR21","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1002\/(SICI)1099-1492(199906)12:4<189::AID-NBM557>3.0.CO;2-O","volume":"12","author":"T Reese","year":"1999","unstructured":"Reese T, Bochelen D, Sauter A, Beckmann N, Rudin M (1999) Magnetic resonance angiography of the rat cerebrovascular system without the use of contrast agents. NMR Biomed 12(4):189\u2013196","journal-title":"NMR Biomed"},{"issue":"2","key":"3251_CR22","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1002\/1522-2594(200008)44:2<252::AID-MRM12>3.0.CO;2-G","volume":"44","author":"N Beckman","year":"2000","unstructured":"Beckman N (2000) High resolution magnetic resonance angiography non-invasively reveals mouse strain differences in the cerebrovascular anatomy in vivo. Magn Reson Med 44(2):252\u2013258","journal-title":"Magn Reson Med"},{"issue":"3","key":"3251_CR23","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/mrm.1910340303","volume":"34","author":"SG Kim","year":"1995","unstructured":"Kim SG (1995) Quantification of relative cerebral blood flow change by flow-sensitive alternating inversion recovery (FAIR) technique application to functional mapping. Magn Reson Med 34(3):293\u2013301","journal-title":"Magn Reson Med"},{"issue":"1","key":"3251_CR24","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/mrm.1910230106","volume":"23","author":"JA Detre","year":"1992","unstructured":"Detre JA, Leigh JS, Williams DS, Koretsky AP (1992) Perfusion imaging. Magn Reson Med 23(1):37\u201345","journal-title":"Magn Reson Med"},{"issue":"4","key":"3251_CR25","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1002\/mrm.21549","volume":"59","author":"J Xie","year":"2008","unstructured":"Xie J, Gallichan D, Gunn RN, Jezzard P (2008) Optimal design of pulsed arterial spin labelling MRI experiments. Magn Reson Med 59(4):826\u2013834","journal-title":"Magn Reson Med"},{"issue":"1","key":"3251_CR26","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/jcbfm.1985.9","volume":"5","author":"P Herscovitch","year":"1985","unstructured":"Herscovitch P, Raichle ME (1985) What is the correct value for the brain-blood partition coefficient for water? J Cereb Blood Flow Metab 5(1):65\u201369","journal-title":"J Cereb Blood Flow Metab"},{"issue":"1","key":"3251_CR27","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/mrm.10676","volume":"51","author":"F Kober","year":"2004","unstructured":"Kober F, Iltis I, Izquierdo M, Desrois M, Ibarrola D, Cozzone PJ et al (2004) High-resolution myocardial perfusion mapping in small animals in vivo by spin-labelling gradient-echo imaging. Magn Reson Med 51(1):62\u201367","journal-title":"Magn Reson Med"},{"issue":"11","key":"3251_CR28","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1038\/jcbfm.2010.160","volume":"30","author":"C Leithner","year":"2010","unstructured":"Leithner C, Muller S, Fuchtemeier M, Lindaur U, Dirnagl U, Royl G (2010) Determination of the brain-blood partition coefficient for water in mice using MRI. J Cereb Blood Flow Metab 30(11):1821\u20131824","journal-title":"J Cereb Blood Flow Metab"},{"issue":"5","key":"3251_CR29","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.mri.2006.10.020","volume":"25","author":"MC Dobre","year":"2007","unstructured":"Dobre MC, U\u011furbil K, Marjanska M (2007) Determination of blood longitudinal relaxation time (T1) at high magnetic field strengths. Magn Reson Imaging 25(5):733\u2013735","journal-title":"Magn Reson Imaging"},{"issue":"3","key":"3251_CR30","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1016\/j.neuroimage.2006.01.015","volume":"31","author":"PA Yushkevich","year":"2006","unstructured":"Yushkevich PA, Piven J, Hazlett HC, Smith RG, Ho S, Gee JC et al (2006) User-guided 3D active contour segmentation of anatomical structures: significantly improved efficiency and reliability. Neuroimage. 31(3):1116\u20131128","journal-title":"Neuroimage."},{"issue":"1","key":"3251_CR31","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S0306-4522(01)00396-7","volume":"108","author":"BP Meloni","year":"2001","unstructured":"Meloni BP, Majda BT, Knuckey NW (2001) Establishment of neuronal in vitro models of ischemia in 96 well microtitre strip-plates that result in acute, progressive and delayed neuronal death. Neuroscience. 108(1):17\u201326","journal-title":"Neuroscience."},{"issue":"3","key":"3251_CR32","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1515\/BC.2003.044","volume":"384","author":"A Elmquist","year":"2003","unstructured":"Elmquist A, Langel U (2003) In vitro uptake and stability study of pVEC and its all-D analog. Biol Chem 384(3):387\u2013393","journal-title":"Biol Chem"},{"issue":"2","key":"3251_CR33","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1073\/pnas.0407677102","volume":"102","author":"R Tugyi","year":"2005","unstructured":"Tugyi R, Uray K, Iv\u00e1n D, Fellinger E, Perkins A, Hudecz F (2005) Partial D-amino acid substitution: improved enzymatic stability and preserved Ab recognition of a MUC2 epitope peptide. Proc Natl Acad Sci U S A 102(2):413\u2013418","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"3251_CR34","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1007\/s11064-020-03004-3","volume":"45","author":"JE Kenna","year":"2020","unstructured":"Kenna JE, Anderton RS, Knuckey NW, Meloni BP (2020) Assessment of recombinant tissue plasminogen activator (rtPA) toxicity in cultured neural cells and subsequent treatment with poly-arginine peptide R18D. Neurochem Res 45(5):1215\u20131229","journal-title":"Neurochem Res"},{"issue":"2","key":"3251_CR35","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s11095-015-1791-2","volume":"33","author":"LH Leithold","year":"2016","unstructured":"Leithold LH, Jiang N, Post J, Ziehm T, Schartmann E, Kutzsche J et al (2016) Pharmacokinetic properties of a novel D-peptide developed to be therapeutically active against toxic \u03b2-amyloid oligomers. Pharm Res 33(2):328\u2013336","journal-title":"Pharm Res"},{"issue":"6","key":"3251_CR36","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1089\/08892220151126508","volume":"17","author":"BJ Doranz","year":"2001","unstructured":"Doranz BJ, Filion LG, Diaz-Mitoma F, Sitar DS, Sahai J, Baribaud F et al (2001) Safe use of the CXCR4 inhibitor ALX40-4C in humans. AIDS Res Hum Retrovir 17(6):475\u2013478","journal-title":"AIDS Res Hum Retrovir"}],"container-title":["Neurochemical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11064-021-03251-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11064-021-03251-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11064-021-03251-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,17]],"date-time":"2021-04-17T08:19:39Z","timestamp":1618647579000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11064-021-03251-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,1]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["3251"],"URL":"https:\/\/doi.org\/10.1007\/s11064-021-03251-y","relation":{},"ISSN":["0364-3190","1573-6903"],"issn-type":[{"value":"0364-3190","type":"print"},{"value":"1573-6903","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,1]]},"assertion":[{"value":"16 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Bruno P. Meloni and Neville W. Knuckey are the holders of several patents regarding the use of arginine-rich peptides as neuroprotective treatments. Diego Milani, Vince W. Clark, Ryan S. Anderton, David J. Blacker, Adam Edwards, Neville W. Knuckey, and Bruno P. Meloni are shareholders in Argenica Therapeutics, which is a company developing R18 as a stroke therapeutic. The other authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All work was performed in compliance with the Animal Ethics Committee of the University of Western Australia and following the guidelines outlined by the <i>Australian Code for the Care and Use of Animals for Scientific Purposes.<\/i>","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}